ArticleJournal of cellular and molecular medicine2026
Toxoplasma gondii-Derived Soluble Factors Induce G2/M Phase Accumulation and p53-Associated Mitochondrial Apoptosis in Human Umbilical Cord Mesenchymal Stem Cells.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Toxoplasma gondii infection poses potential risks to stem cell-based therapeutic applications; however, the effects of parasite-derived soluble factors on mesenchymal stem cells remain unclear. Here, we investigated the impact of T. gondii-derived soluble factors (Tg-SFs) on human umbilical cord-derived mesenchymal stem cells (hUC-MSCs). hUC-MSCs were exposed to Tg-SFs generated in a Transwell co-culture system, and cellular phenotypes and p53 signalling were analysed using integrated functional and molecular approaches. Tg-SFs induced upper-chamber multiplicity of infection (MOI)-dependent cytotoxicity in hUC-MSCs, accompanied by cytoskeletal remodelling and nuclear condensation. Tg-SFs exposure caused marked G2/M phase accumulation, which was accompanied by reduced expression of Cyclin A2, Cyclin B1, and Cyclin E2 and increased p21 expression. In addition, Tg-SFs exposure reduced phosphorylation of CDK1 at Thr161. Tg-SFs-exposed hUC-MSCs underwent significant apoptosis, as evidenced by PARP and Caspase-3 cleavage. Mechanistically, Tg-SFs promoted accumulation of total p53 protein and selective phosphorylation of p53 at Ser15 and Ser392, and modulated Bcl-2 family proteins by upregulating Bax, BID, Bak, Bad, and Puma while downregulating Bcl-xL and Mcl-1. Pharmacological inhibition of p53 with PFT-α and siRNA-mediated p53 knockdown partially reversed these effects, indicating that p53 signalling contributes substantially, but not exclusively, to Tg-SFs-induced mitochondrial apoptosis. These findings indicate that T. gondii-derived soluble factors impair hUC-MSC viability through G2/M phase accumulation and p53-associated mitochondrial apoptosis, highlighting a potential safety consideration for MSC-based applications under parasite-associated conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.